surmount-1 tirzepatide weight loss nondiabetic Read now: The SURPASS-EARLY trial found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m Surmount Press Briefing #ADA2022

And a study published in January 2025 suggested that popular GLP-1 medications approved for weight loss, diabetes and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections and some kinds of cancer and dementia

Discussing potential side effects thoroughly with a healthcare provider is important for anyone considering these medications

A clinical trial, begun in Tijuana around 2015 and sponsored by a Croatian company that lists Sikiric as a partial owner, is listed as canceled in a U.S

In recent years, diet-based approaches and nutritional supplementation have gained extensive attention for managing NAFLD/MASLD

Mannitol (23.2 mg in 0.5 mL): Used primarily as a tonicity agent, mannitol helps adjust the osmolarity of the injection solution to be compatible with body fluids

J Pharmacol Exp Ther (2000) 293(3):7718